Anal Squamous Cell Carcinoma: 5 Things to Know
Recent advancements—including novel chemoradiation strategies, targeted therapies, and immune‑checkpoint inhibitors—are reshaping the therapeutic landscape for anal squamous cell carcinoma (ASCC).
This Medscape commentary outlines current knowledge on ASCC, emphasizing its rising incidence, the central role of high‑risk HPV infection, and emerging therapeutic options—including immune checkpoint inhibitors, targeted agents, and precision radiotherapy—that are improving outcomes for both early‑stage and advanced disease. It also discusses practical aspects of early detection, staging, and the evolving treatment paradigm.
Understanding the latest evidence‑based strategies for ASCC is critical for clinicians because early‑stage disease can be effectively treated with chemoradiation, while advanced disease now benefits from multiple novel modalities, including immunotherapy, that can extend survival and improve quality of life.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity‑Modulated Radiation Therapy
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Advancements in Immunotherapy for Anal Cancer Treatment
- Background and Current Treatment of Squamous Cell Carcinoma of the Anus
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden